结合使用图卡替尼和特拉斯图祖马布的第二期试验显示,在46. 7%的胆道癌患者中有效;需要进一步研究. Phase II trial shows combination of tucatinib and trastuzumab effective in 46.7% bile duct cancer patients; further research needed.

一项II期试验表明,针对HER2蛋白的药物图卡替尼和特拉斯图祖马布的组合可能对胆道癌患者有效. A phase II trial suggests that the combination of tucatinib and trastuzumab, drugs targeting the HER2 protein, may be effective for patients with bile duct cancer. 在30名胆管癌患者中,46. 7%的患者出现瘤缩小,而217名参与者的整体应答率为22. 2%. Among 30 bile duct cancer patients, 46.7% experienced tumor shrinkage, while the overall response rate was 22.2% across 217 participants. 治疗耐受性良好,但需要进一步研究来验证这些发现,并可能将药物组合纳入治疗HER2阳性胆道癌的临床指南. The treatment was well-tolerated, but further research is needed to validate these findings and potentially include the drug combination in clinical guidelines for HER2-positive bile duct cancer.